AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04695093 — intervention group
Intervention type: OTHER
Intervention: Ultra Low Emission Zone (ULEZ)
Description: The ULEZ comprises a Central London zone, implemented on 8th April 2019, within which polluting vehicles are subject to a charge. Using number plate recognition technology, a daily penalty charge notice is issued for vehicles entering this central zone not meeting the standard of Euro 4 for petrol, Euro 6/VI for diesel, and Euro for motorcycles.~The ULEZ will subsequently be extended to include:~1. In 2020, a London-wide ULEZ for heavy duty vehicles (HDV) within the LEZ boundary (green zone). HDVs not meeting Euro 6 standard will be charged daily.~2. In 2021, an Inner London ULEZ area for all light duty vehicles (LDV) within the boundary of the North and South Circular Roads (yellow zone). Vehicles not meeting the above criteria will be charged daily as for the Central London area.
Study NCT05951322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave therapy
Description: Radial extracorporeal shock wave device, it is serial number (1107394), medispec and connected to electrical supply 115/220 A C frequency.
Study NCT05951322 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phonophoresis
Description: Pagani ultrasound apparatus 200 cosistts of multi frequency head(1 and 3 MHz), surface area 4 cm², continuous and pulsed mode, main voltages: 100-240-VAC.50/60Hz.
Study NCT05888662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endo-epicardial ablation
Description: Endo-epicardial ablation of ventricular tachycardia
Study NCT05888662 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endocardial ablation only
Description: endocardial-only catheter ablation of ventricular tachycardia
Study NCT05799638 — intervention group
Intervention type: OTHER
Intervention: Guideline-Directed Medication Treatment (GDMT)
Description: GDMT contains ACEIs/ARBs/ARNI, β blockers, SGLT2is, MRAs. ACEI/ARB/ARNI and β blocker will gradually be titrated up to the maximum tolerable dose
Study NCT04939480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg intravenous solution
Study NCT04088981 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Low-fat, plant-based diet and a portion-controlled diet
Study NCT05724186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test myopia control lenses (CSL)
Description: A pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
Study NCT05778305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: a central sympatholytic drug
Study NCT05778305 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: saline is given to control group
Study NCT06442436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: 25 mg nemtabrutinib (1 x 5 mg and 1 x 20 mg tablets) administered orally as a single dose.
Study NCT05160922 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: crizotinib
Description: crizotinib oral treatment
Study NCT06636617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.70 GBq (100 mCi) of 177Lu-JH04
Description: All 3 patients were intravenous injected with single dose 3.70 GBq (100 mCi) of 177Lu-JH04.
Study NCT06636617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5.55 GBq (150 mCi) of 177Lu-JH04
Description: All 3 patients were intravenous injected with single 5.55 GBq (150 mCi) of 177Lu-JH04
Study NCT06636617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7.40 GBq (200 mCi) of 177Lu-JH04
Description: All 3 patients were intravenous injected with single 7.40 GBq (200 mCi) of 177Lu-JH04
Study NCT06635564 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Viscoelastic testing
Description: viscoelasting testing refers to a global hemostatic assay,that quantifies the viscoelastic properties of citrated whole blood
Study NCT05234944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes and Life
Description: Brief behavioral intervention, delivered remotely by certified diabetes care and education specialists, targeting diabetes-specific health-related quality of life for people with type 1 diabetes across the lifespan and for their parents and partners.
Study NCT06525181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Generative Artificial Intelligence
Description: Gen AI assisted symptom intake summarization
Study NCT06525181 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard weekly symptom intake
Description: Standard weekly symptom intake performed by a physician
Study NCT05505708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxyethyl starch in sodium chloride injection Brand Name: Voluven
Description: (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) is a clear to slightly opalescent, colorless to slightly yellow, sterile, non-pyrogenic, isotonic solution for intravenous administration using sterile equipment.~Each 100 mL of the solution contains: 6 g of Hydroxyethyl Starch 130/0.4 and 900 mg of Sodium Chloride USP in Water for Injection USP.~In addition, sodium hydroxide, USP, or Hydrochloric acid, USP, has been added to adjust the final pH so the final solution pH is 4.0 to 5.5.
Study NCT05505708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline solution
Description: Within each 100 mL of 0.9% sodium chloride Injection USP, there is 15.4 mEq of sodium ions and 15.4 mEq of chloride ions. Additionally, the osmolarity is 308 mOsmol/liter, and it has a pH range of 4.5 to 7
Study NCT05469503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TOTUM-854
Description: 12 weeks of TOTUM-854 supplementation
Study NCT06329635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Nicardipine
Description: First, 6 ml of cerebrospinal fluid is withdrawn from the EVD or LD catheter, and then 4 ml (4mg) of nicardipine is injected into the EVD or LD drain tube, followed by 2 ml normal saline solution, and then the EVD or LD tube is clamped for 2 hours, and then kept open as clinically necessary until the next dose (q12h) of medication.
Study NCT06329635 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No intervention
Description: A simulated intrathecal administration operation is performed by a dedicated physician who is unblinded to the group assignment, the EVD or LD tube is not opened, and no drug is given. The simulated administration process needs to be out of the patient's view (if awake patient) and out of the presence of study team personnel.
Study NCT05215574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGM831
Description: Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
Study NCT05215574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGM831 plus pembrolizumab (KEYTRUDA®)
Description: Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21day cycle.
Study NCT05215574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
Description: Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated.~Drug: NGM438 NGM438 is given intravenously (IV) every 3 weeks in a 21-day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®) pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21-day cycle.
Study NCT05872139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gelatin capsules
Study NCT05872139 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mitoquinone Mesylate
Description: MitoQ was given once (single dose, 80 mg)
Study NCT05970393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pressure support level tatrition
Description: Baseline ventilators were set by the principle of keeping VT/PBW at 6-8ml/kg and RR at 20-30 breaths/min and the decision of the responsible ICU physician. After then the fraction of inspired oxygen (FiO2), positive expiratory end pressure (PEEP), trigger sensitivity, and cycle-off criteria remain unchanged. Upward and downward PS level adjustments were performed from the baseline PS level at a 1cm H2O interval. Every PS level was maintained for 20 minutes and then three end-inspiratory holdings (2-3seconds) and three end-expiratory holdings were performed. PMI mean value was measured and calculated at every PS level. To avoid additional injury to the lung and diaphragm, the airway peak pressure (Ppeak) was limited to 30cmH2O, and titrating PS was stopped until PMI was less than -1cmH2O and more than 3cmH2O.The inspiratory effort is measured as the pressure generated by inspiratory muscles using esophageal pressure monitoring.
Study NCT06111950 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Blood samples of 5 ml to 15 ml depending on their weight
Study NCT05938023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATL1102 25mg
Description: Dose and scheduled as specified in the Arm description
Study NCT05938023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATL1102 50mg
Description: Dose and scheduled as specified in the Arm description
Study NCT06719622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: 1 mg budesonide ampoule twice daily for patients weighing ≤35 kg or 2 mg twice daily for patients weighing >35 kg
Study NCT06719622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole (proton pump inhibitor)
Description: omeprazole 10 mg twice daily for patients weighing ≤35 kg or 20 mg twice daily for patients weighing >35 kg
Study NCT06111950 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Skin biopsies
Description: Biopsies of fragment of skin 2 to 3 mm long by 1 mm wide and 1 mm deep will preferably be taken on the inside of the arm, in the upper third, between the bend of the elbow and the hollow of the armpit under strict sterility conditions.
Study NCT06720805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentabiocel
Description: This is a randomized, double-blind, placebo-controlled, multicenter clinical trial aimed at recruiting 56 pediatric patients with IBS.~The activities will be divided into the following phases:~1. Patient Enrollment Phase: eligible patients will meet the diagnostic criteria for IBS, as defined by internationally recognized guidelines. Informed consent will be obtained from the legal guardians of the participants before their inclusion in the study.~2. Randomization: the enrolled participants will be randomly assigned to one of two groups: the probiotic group or the placebo group.~3. Treatment Phase: a 3-month treatment phase will be conducted with a mixture of 5 strains of lactic acid bacteria and bifidobacter.~4. Follow-up Phase: this will be followed by a 4-week follow-up phase. Clinical data will be monitored throughout the study using validated questionnaires.
Study NCT06720805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a randomized, double-blind, placebo-controlled, multicenter clinical trial aimed at recruiting 56 pediatric patients with IBS.~The activities will be divided into the following phases:~1. Patient Enrollment Phase: eligible patients will meet the diagnostic criteria for IBS, as defined by internationally recognized guidelines. Informed consent will be obtained from the legal guardians of the participants before their inclusion in the study.~2. Randomization: the enrolled participants will be randomly assigned to one of two groups: the probiotic group or the placebo group.~3. Treatment Phase: a 3-month treatment phase will be conducted with a mixture of 5 strains of lactic acid bacteria and bifidobacter.~4. Follow-up Phase: this will be followed by a 4-week follow-up phase. Clinical data will be monitored throughout the study using validated questionnaires.
Study NCT06720740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RELIEF Ureteral Stent
Description: The study intervention is placement of the RELIEF Ureteral Stent
Study NCT06720740 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Ureteral Stent
Description: The control product is the Ascerta stent by Boston Scientific.
Study NCT06720402 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sun protection knowledge
Description: To increase knowledge and awareness about sun protection methods, a presentation will be implented to pediatricians and family physicians.
Study NCT04944784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reldesemtiv
Description: Reldesemtiv Oral Tablet
Study NCT04944784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Oral Tablet
Study NCT05938023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose and scheduled as specified in the Arm description
Study NCT05023915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: 40 mg qd for 4 days
Study NCT05327725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigue Reduction Diet
Description: Participants receive individualized nutrition counseling to adopt the fatigue reduction diet protocol.
Study NCT06423183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Mindful Approach to Building a Resilient Healthcare Workforce (RENEW)
Description: Synchronous, 4-month intervention that teaches skills in mindfulness, stress management, and resilience as an individual and as a team. Sessions occur monthly and include a 1 hour in-person introductory session followed by 3 50-minute virtual sessions.
Study NCT06111950 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fetal samples
Description: Skin, muscle, brain and bone biopsies will be collected from fetuses in the autopsy room after the medical termination of pregnancy or miscarriage
Study NCT06536062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of CB-PRP
Description: The procedure consists in a trans-scleral puncture to access the vitreous cavity, with subsequent injection of CB-PRP
Study NCT04634357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET140203 T Cells
Description: Biological/Vaccine: ET140203 autologous T-cell product~Autologous T cells transduced with lentivirus encoding an ET140203 expression construct
Study NCT05400096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological therapy
Description: The protocol for the group will be developed collaboratively between the chief researcher and the supervisor based in the weight management service. The protocol will contain Compassion Focused Therapy (CFT) based therapeutic approaches, but the group will integrate some Acceptance and Commitment Therapy (ACT) concepts.
Study NCT06439537 — intervention group
Intervention type: OTHER
Intervention: Semi-structured questionnaire
Description: All patients recruited to the study will undergo a semi-structured questionnaire within 36 hours of admission
Study NCT06439537 — intervention group
Intervention type: OTHER
Intervention: Post-operative interview
Description: All patients recruited to the study will undergo a semi-structured interview once they have reached post-operative day 7 or over
Study NCT06057701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: corrective exercises
Description: corrective exercises:~1. Strengthening exercises :~   1. Thoracic extension exercises:~      * Mckanzie's thoracic extension exercise:~     * Thoracic spine stretching position~  2. Back extension exercise~  3. Abdominal curl up exercise~  4. Scapular retraction exercises~  5. Trunk rotation exercise~2. Stretching exercises:~   1. Pectoral muscles stretch from sitting~  2. self-stretch for pectoral muscle infront of door
Study NCT06057701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resisted diaphragmatic breathing exercises
Description: 1. Diaphragmatic breathing exercise: From the supine position, overlapping hands on the diaphragm located in the abdominal region: each woman took deep inspiring by the nose and exhaling through the mouth with lips half-closed slowly.~2. Resisted diaphragmatic breathing exercise: From the supine position, with a weight of 1 kg on the diaphragm located in the abdominal region: each woman took deep inspiring by the nose and exhaling through the mouth with lips half-closed slowly
Study NCT05556512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT05556512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT04832724 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-314
Description: RGX-314 is a recombinant adeno-associated virus gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
Study NCT05469503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 weeks of placebo supplementation
Study NCT06232369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active repetitive deep transcranial magnetic stimulation (dTMS)
Description: Before the intervention, the brain structure of each participant will be captured using an MRI scanner, and individualized spatial coordinates of the hypothesized target will be determined based on these 3D structural images. Then the resting motor threshold will be tested using the method of thumb twitching observation.~The intervention will employ the H7 coil that is accurately delivered to the intended target by an optic navigation and a deep pulse protocol at 90% of the tested threshold for 15-minute stimulation duration.
Study NCT06232369 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive deep transcranial magnetic stimulation (dTMS)
Description: Before the intervention, the brain structure of each participant will be captured using an MRI scanner, and individualized spatial coordinates of the hypothesized target will be determined based on these 3D structural images. Then the resting motor threshold will be tested using the method of thumb twitching observation.~The intervention will employ the H7 coil that is placed on the scalp to mimic the sensation and sounds of the actual treatment but without letting the magnetic field reach the brain tissue for 15-minute duration.
Study NCT05294198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot extract
Description: Beetroot extract capsule
Study NCT05294198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot extract
Description: Beetroot extract capsule
Study NCT05285917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Hydroxyurea has a narrow therapeutic window such that selection of the correct dose is essential to optimize benefits and avoid toxicity.
Study NCT05285917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Hydroxyurea has a narrow therapeutic window such that selection of the correct dose is essential to optimize benefits and avoid toxicity.
Study NCT06537856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Belief Model Based Cardiovascular Disease Risk Factor Prevention Education
Description: In line with the literature review, Health Belief Model-Based Cardiovascular Disease Risk Factor Prevention Training was created in order to increase the level of knowledge of firefighters regarding cardiovascular disease risk factors, improve their awareness and positively affect their quality of life. This training was given in 3 different sessions by meeting face-to-face with firefighters in the training hall of the fire stations. Each session lasted 40 minutes. Answers were given to the questions asked at the end of the session. The training was organized under the following main headings:~Perceived Sensitivity, Perceived Seriousness, Perceived Barriers, Perceived Self-Efficacy, Health Motivation/Activators
Study NCT06537856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder Short Messages
Description: After the Health Belief Model-Based health education, 39 text messages were sent via WhatsApp application 3-4 times a week for 3 months to increase the effectiveness of the education and the motivation of firefighters in CVD prevention.
Study NCT05764902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-tailored intervention
Description: The intervention group will receive various tailored interventions designed to address multiple patient preferences, including sleeping, eating, and resting habits, hobbies, visitation preferences, religious and spiritual needs, preferences for independence and privacy, and any other specific requests or requirements.
Study NCT05787860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib 1.5% Cream
Description: topical ruxolitinib 1.5% cream twice daily for 4 weeks
Study NCT05880420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caregiver operations with medication accessories
Description: After at least an initial outpatient medication (24/72 hours), home medication every 7 days (caregiver) for a total of 10 weeks.
Study NCT05880420 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nurse operations with medication accessories
Description: Outpatient medication every week (for a total of 10 weeks). Patients adhering to this arm will be followed at the IGAV nursing clinic of the IFOs.
Study NCT04870931 — intervention group
Intervention type: PROCEDURE
Intervention: TEM / TEM-ESD
Description: Transanal local excision of a rectal tumour as a conventional, full-thickness TEM or submucosal dissection as TEM-ESD